Sprionaloctone

NHS England, based in Leeds, is currently in the planning stage of a procurement process for a project titled "Spironolactone". This planning involves a Preliminary Market Engagement Notice for a licence variation concerning spironolactone use for acne in women. The relevant industry category is health services, and the project is set to take place primarily in Leeds, United Kingdom.

Key milestones include the availability of the Request for Information (RFI) from 25 February 2025 and the deadline for responses and 1:1 meetings by 12:00 noon on 11 March 2025. The procurement method follows engagement with the market, allowing for supplier feedback and discussions before tendering takes place. This tender offers considerable opportunities for businesses specialising in healthcare and pharmaceutical services, particularly those with expertise in marketing authorisations.

Specifically, there are two contracts available: one for preparing an application for a type II major MHRA Marketing Authorisation variation and another for submitting a pre-prepared application to the MHRA. The tender is suited for current Marketing Authorisation Holders of spironolactone, with potential for significant business growth derived from successful partnership with NHS England in delivering these critical health services. Small and medium-sized enterprises (SMEs) with relevant experience are encouraged to engage in this market exercise.